ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1700

Prevalence of Spondyloarthritis in Anterior Uveitis Patients: The Sentinel Study

Miguel Cordero Coma1 and Xavier Juanola2, 1Department of Ophthalmology, Unidad de Uveítis. Hospital Universitario de León, León, Spain, 2Rheumatology, University Hospital Bellvitge, Barcelona, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Comorbidity and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Anterior uveitis (AU) is the most common form of uveitis in western countries with an annual incidence rate of about eight new cases for every 100,000 inhabitants. AU may occur in the absence of associated systemic disease. However, it has been reported that about 25% of AU patients have an associated systemic condition; the most commonly associated one being seronegative spondyloarthritis (SpA). Since many of the conditions initially diagnosed as idiopathic anterior uveitis are later found to be a SpA-associated disorder, we hypothesised that a higher than expected rate of associated-SpA might be found by using a systematic clinical evaluation protocol in AU patients.

Methods: Prospective multicentre non-comparative cohort study. Patients with no previous diagnosis of any associated immune-mediated condition and clinically significant AU were included in this study. Clinically significant AU was defined as either recurrent AU (at least two episodes) or non-recurrent HLAB27 + associated AU. All patients included in the study underwent a complete physical and ophthalmologic examination and a thorough check-up of their systems including x-ray and MRI study of the sacroiliac joints, for those in which SpA was clinically suspected.

Results: A total of 199 patients from 29 tertiary referral centres were included in the study. From all included patients suffering from AU, 148 patients (74.3%) were HLAB27+. After an initial systematic clinical evaluation protocol, 122 patients (61.3%) were newly diagnosed with a type of spondyloarthritis, of which 94 patients (47.2%) fullfilled the ASAS criteria for axial spondyloarthritis and 28 patients (14%) fullfilled the ASAS criteria for peripheral spondyloarthritis. A positive HLAB27 haplotype was found in 89 (94%) of patients newly diagnosed with axial spondyloarthritis and in 20 (71.4%) of those patients newly diagnosed with peripheral spondyloarthritis. Other associated diagnoses included ankylosing spondylitis, diagnosed based on New York criteria, in 78 patients (39.2%), psoriasis in 10 patients (5%), inflammatory bowel disease in 3 patients (1.5%), and reactive arthritis in 1 patient (0.5%).

Conclusion: These preliminary results show that in a large prospective cohort almost 75% of patients with clinically significant idiopathic AU have an associated underlying SpA which more than double that of previously reported prevalence. The diagnosis of idiopathic uveitis seems to depend greatly on the extent of the evaluation for an underlying condition. These results should be considered in the management and therapeutic decision-making for patients with recurrent AU.


Disclosure:

M. Cordero Coma,
None;

X. Juanola,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-spondyloarthritis-in-anterior-uveitis-patients-the-sentinel-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology